On the Record · AbbVie
AbbVie acquisitions, on the record
The businesses AbbVie bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Cerevel Therapeutics Holdings, Inc.Word for word“On December 6, 2023, AbbVie announced that it entered into a definitive agreement under which AbbVie will acquire Cerevel Therapeutics Holdings, Inc. (Cerevel Therapeutics).” 10-K for 2023 | agreed acquisition | On December 6, 2023 | — |
ImmunoGen, Inc.Word for word“Subsequent to 2023, on February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen, Inc. (ImmunoGen).” 10-K for 2023 | acquisition | on February 12, 2024 | — |
DJS Antibodies LtdWord for word“The aggregate purchase price of $ 287 million was comprised of a $ 255 million upfront cash payment and $ 32 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $ 95 million in future payments upon achievement of certain development milestones.” 10-K for 2023 | acquisition | — | $ 287 million |
Soliton, Inc.Word for word“Total consideration transferred allocated to the purchase price consisted of cash consideration of $ 535 million paid to holders of Soliton common stock, equity-based awards and warrants.” 10-K for 2023 | acquisition | — | cash consideration of $ 535 million |
Syndesi Therapeutics SAWord for word“Under the terms of the agreement, AbbVie made an upfront payment of $ 130 million which was recorded to acquired IPR&D and milestones expense in the consolidated statement of earnings in the first quarter of 2022.” 10-K for 2023 | acquisition | — | upfront payment of $ 130 million |
Pylera (worldwide commercial rights, sold to Juvise Pharmaceuticals)Word for word“In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori.” 10-K for 2023 | divestiture | In June 2022 | — |
TeneoOne and TNB-383BWord for word“In September 2021, AbbVie acquired TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM).” 10-K for 2023 | acquisition | In September 2021 | — |
Aliada Therapeutics Holdings, Inc.Word for word“Acquired IPR&D and milestones expense in 2024 included charges related to the upfront payments of $1.4 billion to acquire Aliada Therapeutics Holdings, Inc. (Aliada) and $250 million to acquire Celsius Therapeutics.” 10-K for 2024 | acquisition | — | $1.4 billion |
Celsius TherapeuticsWord for word“Acquired IPR&D and milestones expense in 2024 included charges related to the upfront payments of $1.4 billion to acquire Aliada Therapeutics Holdings, Inc. (Aliada) and $250 million to acquire Celsius Therapeutics.” 10-K for 2024 | acquisition | — | $250 million |
Nimble Therapeutics, Inc.Word for word“On January 23, 2025, AbbVie completed its acquisition of Nimble Therapeutics, Inc. (Nimble). ” 10-K for 2025 | acquisition | January 23, 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $2.5 billion | $2.36 billion |
| 2017-12-31 | $0 | — |
| 2018-12-31 | $0 | — |
| 2019-12-31 | $0 | — |
| 2020-12-31 | $38.26 billion | $17.01 billion |
| 2021-12-31 | $525 million | $177 million |
| 2022-12-31 | $255 million | $92 million |
| 2023-12-31 | $0 | — |
| 2024-12-31 | $17.49 billion | $2.95 billion |
| 2025-12-31 | $204 million | $170 million |
Deal filings since 2016
- 2023-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-05-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-08 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-11-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-08-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-06-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-09-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-09-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-11-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-05-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-05-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-04-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from AbbVie’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.